The Canada Self-Monitoring Blood Glucose Market size is estimated at USD 391.84 million in 2024, and is expected to reach USD 542.16 million by 2029, growing at a CAGR of 6.71% during the forecast period (2024-2029).
Diabetes Canada 2021 says that since the start of the COVID-19 pandemic, studies showed that diabetes was one of the major comorbidities linked to severe COVID-19-related negative outcomes and death.When adults with diabetes got COVID-19, they were more likely to get adult respiratory distress syndrome, pneumonia, excessive, out-of-control inflammatory responses, and a state called "hypercoagulable."Early reports placed the odds of in-hospital death from COVID-19 at 2.85 times higher in adults living with diabetes compared to patients without diabetes. Experts say that inpatient use of diabetes technology in patients who followed the institution's rules was safe, improved inpatient glycemic outcomes, and was a key part of managing hypoglycemia and hyperglycemia in hospitalized patients.
Blood glucose monitoring increases patients' awareness of glucose values, which supports healthy lifestyle choices. Blood Glucose Monitoring values help in providing feedback and guidance on how to make health behavior changes when needed. Continued elevation in blood glucose levels in diabetes patients can contribute to progressive complications such as renal, nerve, and ocular damage. Appropriate and timely monitoring of blood glucose allows the successful management of out-of-range blood glucose levels, minimizing diabetic-related health complications.
Innovative technologies, such as digital health apps that show and summarize each person's blood glucose readings and add other relevant data like insulin doses, meals or snacks, and physical activity, can help people better manage their own diabetes while reducing the burden of the disease and improving care overall. Integration of Blood Glucose Monitoring with insulin calculators, automated insulin titration software, and remote coaching are all new developments that give patients with poorly controlled diabetes the extra help they need to improve critical outcomes, which will improve the market prospects in the years to come.
Monitoring blood glucose levels is a good addition to other ways to measure glycemia, such as the A1C. It is the optimal way to confirm and appropriately treat hypoglycemia. It can provide feedback on the results of healthy behavior interventions and antihyperglycemic pharmacological treatments. It can increase one's empowerment and adherence to treatment. It can also provide information to both the person with diabetes and their diabetes healthcare team to facilitate longer-term treatment modifications and titrations as well as shorter-term treatment decisions, such as insulin dosing for people with type 1 or type 2 diabetes. In situations where A1C does not accurately reflect glycemia, monitoring blood glucose is necessary to adequately monitor glycemia.
Monitoring blood glucose works best when it's part of an education program that teaches people with diabetes how to change their behavior for the better based on their blood glucose levels and teaches healthcare providers how to change antihyperglycemic drugs based on blood glucose readings. As part of this education, people with diabetes should learn how and when to self-monitor, how to keep track of their results in an organized way, what different blood glucose levels mean, and how their actions and behaviors affect their blood glucose results.
The Canadian Diabetes Strategy (CDS) is a national partnership that includes the provinces and territories, many national health organizations and interest groups, and Aboriginal communities across the country. The goal of the CDS is to come up with and set up effective ways for Canada to prevent and control diabetes. With all of its partners' knowledge and experience at its disposal, the CDS is in a good position to figure out where the needs and gaps are and make sure that resources are put where they are needed.
Because of this, it is expected that the studied market will grow over the period of the analysis. This is because the problem is becoming more common and more people are learning about it thanks to government initiatives.
Glucose monitoring gives people living with diabetes a more complete picture of their blood sugar levels, which can influence short- and long-term treatment decisions and improve health outcomes. It lets them and their doctors figure out the glycemic status and any negative effects, as well as how well glucose-lowering therapies work.Glucose monitoring could help people with diabetes better control their blood sugar and improve their quality of life. This could lead to physical, social, emotional, and functional benefits.
Capillary blood glucose monitoring or self-monitoring of blood glucose is one way for people living with diabetes to measure and assess their glucose levels. It uses a drop of blood from a finger prick to get a blood glucose reading using a blood glucose meter, or glucometer. People with diabetes should talk to their care team about how often and how they should be tested.In Canada, CBG test strips cost, on average, $0.79 each. Reimbursement from the government for test strips is provided through provincial drug plans and is based on the prescribed course of treatment, age, and income.
The market players are adopting various strategies, such as collaborations, partnerships, mergers, acquisitions, and expansions, to increase their market share. For instance, in May 2021, Roche Diabetes Care Canada announced a collaboration with Ellerca Health, a Toronto-based company dedicated to improving patient care through innovation and technology. The partnership included the launch of Accu-Chek and 360Care, combining Roche's Accu-Chek Guide blood glucose meter, customized home delivery of testing strips, and Ellerca's self-management digital program, 360Care, which empowers patients to be in control of their treatment schedule with access to a team of health coaches.
Thus, owing to the above-mentioned factors, it is expected to drive the segment's growth over the forecast period.
This product will be delivered within 2 business days.
Diabetes Canada 2021 says that since the start of the COVID-19 pandemic, studies showed that diabetes was one of the major comorbidities linked to severe COVID-19-related negative outcomes and death.When adults with diabetes got COVID-19, they were more likely to get adult respiratory distress syndrome, pneumonia, excessive, out-of-control inflammatory responses, and a state called "hypercoagulable."Early reports placed the odds of in-hospital death from COVID-19 at 2.85 times higher in adults living with diabetes compared to patients without diabetes. Experts say that inpatient use of diabetes technology in patients who followed the institution's rules was safe, improved inpatient glycemic outcomes, and was a key part of managing hypoglycemia and hyperglycemia in hospitalized patients.
Blood glucose monitoring increases patients' awareness of glucose values, which supports healthy lifestyle choices. Blood Glucose Monitoring values help in providing feedback and guidance on how to make health behavior changes when needed. Continued elevation in blood glucose levels in diabetes patients can contribute to progressive complications such as renal, nerve, and ocular damage. Appropriate and timely monitoring of blood glucose allows the successful management of out-of-range blood glucose levels, minimizing diabetic-related health complications.
Innovative technologies, such as digital health apps that show and summarize each person's blood glucose readings and add other relevant data like insulin doses, meals or snacks, and physical activity, can help people better manage their own diabetes while reducing the burden of the disease and improving care overall. Integration of Blood Glucose Monitoring with insulin calculators, automated insulin titration software, and remote coaching are all new developments that give patients with poorly controlled diabetes the extra help they need to improve critical outcomes, which will improve the market prospects in the years to come.
Canada Self-Monitoring Blood Glucose Market Trends
Rising Diabetes Prevalence in Canada
In the current year, according to Diabetes Canada, more than 5.7 million Canadians are living with diagnosed diabetes (type 1 or type 2 diabetes); however, 11.7 million Canadians are living with diabetes or prediabetes, a condition that, if left unmanaged, can develop into type 2 diabetes. Diabetes is also costing the healthcare system USD 30 billion per year to treat people with diabetes.Monitoring blood glucose levels is a good addition to other ways to measure glycemia, such as the A1C. It is the optimal way to confirm and appropriately treat hypoglycemia. It can provide feedback on the results of healthy behavior interventions and antihyperglycemic pharmacological treatments. It can increase one's empowerment and adherence to treatment. It can also provide information to both the person with diabetes and their diabetes healthcare team to facilitate longer-term treatment modifications and titrations as well as shorter-term treatment decisions, such as insulin dosing for people with type 1 or type 2 diabetes. In situations where A1C does not accurately reflect glycemia, monitoring blood glucose is necessary to adequately monitor glycemia.
Monitoring blood glucose works best when it's part of an education program that teaches people with diabetes how to change their behavior for the better based on their blood glucose levels and teaches healthcare providers how to change antihyperglycemic drugs based on blood glucose readings. As part of this education, people with diabetes should learn how and when to self-monitor, how to keep track of their results in an organized way, what different blood glucose levels mean, and how their actions and behaviors affect their blood glucose results.
The Canadian Diabetes Strategy (CDS) is a national partnership that includes the provinces and territories, many national health organizations and interest groups, and Aboriginal communities across the country. The goal of the CDS is to come up with and set up effective ways for Canada to prevent and control diabetes. With all of its partners' knowledge and experience at its disposal, the CDS is in a good position to figure out where the needs and gaps are and make sure that resources are put where they are needed.
Because of this, it is expected that the studied market will grow over the period of the analysis. This is because the problem is becoming more common and more people are learning about it thanks to government initiatives.
The Glucometer Devices Segment is expected to witness the highest CAGR over the forecast period
The glucometers segment is expected to have the highest CAGR of about 7.1% in the market over the next few years. This is because glucometers are being used more and more in home care settings, people are becoming more interested in self-monitoring at home, and new, more advanced glucometers have just come out.Glucose monitoring gives people living with diabetes a more complete picture of their blood sugar levels, which can influence short- and long-term treatment decisions and improve health outcomes. It lets them and their doctors figure out the glycemic status and any negative effects, as well as how well glucose-lowering therapies work.Glucose monitoring could help people with diabetes better control their blood sugar and improve their quality of life. This could lead to physical, social, emotional, and functional benefits.
Capillary blood glucose monitoring or self-monitoring of blood glucose is one way for people living with diabetes to measure and assess their glucose levels. It uses a drop of blood from a finger prick to get a blood glucose reading using a blood glucose meter, or glucometer. People with diabetes should talk to their care team about how often and how they should be tested.In Canada, CBG test strips cost, on average, $0.79 each. Reimbursement from the government for test strips is provided through provincial drug plans and is based on the prescribed course of treatment, age, and income.
The market players are adopting various strategies, such as collaborations, partnerships, mergers, acquisitions, and expansions, to increase their market share. For instance, in May 2021, Roche Diabetes Care Canada announced a collaboration with Ellerca Health, a Toronto-based company dedicated to improving patient care through innovation and technology. The partnership included the launch of Accu-Chek and 360Care, combining Roche's Accu-Chek Guide blood glucose meter, customized home delivery of testing strips, and Ellerca's self-management digital program, 360Care, which empowers patients to be in control of their treatment schedule with access to a team of health coaches.
Thus, owing to the above-mentioned factors, it is expected to drive the segment's growth over the forecast period.
Canada Self-Monitoring Blood Glucose Industry Overview
The Canadian self-monitoring blood glucose market is moderately fragmented, with a few significant and other generic players. Manufacturers like Abbott, LifeScan, F. Hoffmann-La Roche AG, and Ascensia occupy a major share.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 MARKET INDICATORS
7 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Diabetes Care
- Roche Holding AG
- LifeScan
- Trividia Health
- Ascensia Diabetes Care
- Acon Laboratories Inc.
- Agamatrix Inc.
- Bionime Corporation
- Rossmax International Ltd.
- Arkray Inc.
Methodology
LOADING...
